Nalaganje...
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in...
Shranjeno v:
| izdano v: | J Transl Med |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5549368/ https://ncbi.nlm.nih.gov/pubmed/28789707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-017-1278-5 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|